Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a 'Love Hormone' spray tame Prader-Willi symptoms?

NCT ID NCT02804373

Symptom relief Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether oxytocin nasal spray, sometimes called the 'love hormone,' can improve behavior and eating problems in adults with Prader-Willi syndrome. Fifty participants received either oxytocin or a placebo daily or every three days for 28 days. Researchers measured changes in behavior, eating habits, and brain activity using scans.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oxytocin nasal spray
What this could lead to
If it works, this could offer a new way to ease behavioral and eating problems in Prader-Willi syndrome, improving social function and quality of life.
What could go wrong
This is a small, completed Phase 2/3 trial. Results may not be strong enough to confirm benefit, and oxytocin may not work for everyone or could have side effects like nasal irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

50 people

The number who actually took part.

Started

Jun 2014

Finished

Jun 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Prader-Willi syndrome genetically confirmed * Absence of extension of the QT interval in the electrocardiogram * Absence of hypokalemia Exclusion Criteria: * Psychiatric troubles * Anomalies of the heart rhythm in significant ECG * Hepatic insufficiency * Renal insufficiency * Patients presenting a pregnancy or breast-feeding * High sensibility to OT * High sensibility to the excipients of the product * Patients having family history of genetic pathology causing an extension of the interval QT * Patients having risk factors of advanced twist

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prader-Willi syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Prader-Willi syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prader-Willi syndrome

Contacts and locations

Locations

  • Centre de référence Prader-Willi - Hôpital Purpan

    Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.